Efficiency and safety of corticosteroid in pericarditis: Review

Modhi Saleh Alburaidi, Manal Ali Baaleis, Musaab Saad Alsaad, Lama Hussamuddin Sallout, Rha Tariq Ismail, Shehana Abdulhafed Bin Shigair, Aljowharah Saud Alotaibi, Ruzan Mohammed Saleh

Abstract:

An improved understanding of how pericarditis develops is critical to prevent this complication, and further research is needed into the pathogenesis of recurrences. We discuss the aetiology and diagnosis of pericarditis, and extensively review the corticoid treatment options for this condition and it's indication and side effects. We conducted a literature search through Scopus, Medline, and PubMed databases independently for all English language publish studies up to December 2017, search was performed using the terms "(pericarditis) AND (corticosteroids) AND (treatment). Corticosteroid treatment was previously the initial choice for treating pericarditis with pericardial effusions or recurrences not reacting to aspirin or NSAIDs. Corticosteroids could usually be effectively utilized to accomplish quick control of symptoms and decrease of pericardial effusion. Nonetheless, more just recently, this therapy has been shown to be associated with more negative results, potentially a more prolonged illness course, especially if used at high dosages. The reported negative effects include enhanced appetite, acne, mood changes and mental health issue (depression, anxiety, insomnia), muscle weakness, fatty deposits in the face, stretch marks across the body (Cushing syndrome), osteoporosis, diabetes mellitus, systemic arterial hypertension, glaucoma and cataract, enhanced risk of infections, and damaged growth in children. All these adverse effects have been reported in patients with recurring and chronic types of pericarditis after prolonged treatment with corticosteroids.

Introduction:

Pericarditis is the most common kind of pericardial illness around the world [1] - [8] Pericarditis usually influences young and middle aged individuals and frequently recurs [1], [2].In a possible, observational cohort research study including 2 general health centers from an Italian urban location of 220 000 citizens, an occurrence of 27.7 situations per 100 000 populace annually was reported [3].Information from a Finnish nationwide computer system registry [4] demonstrateda standardized occurrence rate of hospital stays for acute pericarditis of 3.32 per 100 000 personyears, with a higher percentage of guys. Overall, pericarditis accounts for 0.2% of all hospital cardiovascular admission [4] and is diagnosed in roughly 5% of patients with nonischemic chest discomfort in emergency departments in North America and Western Europe [5], [6].In developed countries, the in-hospital death rate is around 1.1%. Diagnosis is determined partly by patient age and etiology [4], [7].Pericarditis could be an indication of underlying systemic illness or a primary procedure unrelated to systemic disease (table1) [4], [8].Acute and recurring pericarditis are frequently come across professional entities. Provided that severe complications such as tamponade and constrictive pericarditis take place rarely, most of patients dealing with acute pericarditis will have a benign medical program. However, pericarditis reoccurrence, with its painful signs and symptoms, is frequent. The pillar of treatment for recurrences is aspirin or NSAIDs, with the adjunct of colchicine [24].Corticosteroids are a second-line alternative to be taken into consideration for particular indications, such as connective tissue condition or maternity; contraindications or intolerance to pain killers, NSAIDs, and/or colchicine; or not enough response to these medicines. In addition, corticosteroids can be included to NSAIDs and colchicine in patients with relentless symptoms. In patients who do not react sufficiently to any of these traditional treatments, different therapy choices include azathioprine, intravenous human

immunoglobulins, and anakinra.Limited epidemiological data are available, and the precise incidence is difficult to estimate because light instances may settle without a diagnosis.However, failure to recognize and manage pericarditismay extend the condition training course and rise reoccurrences [9], [10].

Proof for pericarditis treatment has progressed in the last 10 years. The first randomized clinical trials (RCTs) [1], [2] and empirical studies [7] have likely added to improved end results and minimized reoccurrences [1], [2]. Well-defined requirements for medical diagnosis, incorporated imaging, and analysis workup have been recently proposed.

An improved understanding of how pericarditis develops is critical to prevent this complication, and further research is needed into the pathogenesis of recurrences. We discuss the aetiology and diagnosis of pericarditis, and extensively review the corticoid treatment options for this condition and it's indication and side effects.

Methodology:

We conducted a literature search through Scopus, Medline, and PubMed databases independently for all English language publish studies up to December 2017, search was performed using the terms "(pericarditis) AND (corticosteroids) AND (treatment). Cited references within selected articles were also searched to identified more relevant studies, only human subject articles were included in this review.

Discussion:

· Pathophysiology

The etiology of pericarditis could be categorized as infectious or noninfectious (Table 1). The timely acknowledgment of a most likely cause of pericarditis may be vital. In developing nations with a high frequency of tuberculosis, tuberculosis make up around 70% of pericarditis diagnoses and has a high mortality: about 25% at 6 months in the lack of human immunodeficiency infection (HIV) infection and approximately 40% in those with linked HIV infection [8], [9].Tuberculous pericarditis is much less typical in developed nations, representing less compared to 5% of all situations [12], [13]. Immigration might raise these situations in developed countries [9] In Western Europe and North America, concerning 80% to 90% of situations are labeled "idiopathic" after a diagnostic workup, and a lot of are presumed to be viral.5,6 The remaining situations with an identified etiology include, in unselected populaces, neoplastic pericardial illness (5% -10%), systemic inflammatory diseases and pericardial injury syndromes (2% -7%), tuberculous pericarditis (about 4%), and purulent pericarditis (pericardial bleeding potentially creating pericarditis (pericardial injury syndromes) [11], [13].

Table1. Etiology of Pericarditis

Viral (common): Enteroviruses (especially Coxsackieviruses, echoviruses); herpesviruses (especially Epstein-Barr virus, cytomegalovirus, human herpesvirus 6); adenoviruses (especially in children); parvovirus B19	**Bacterial:** Mycobacterium tuberculosis (common; other rare), Coxiella burnetii, Borrelia burgdorferi; rarely other microorganisms, usually as purulent pericarditisb
Fungal (rare): Histoplasma species (more likely in immunocompetent patients); Aspergillus, Blastomyces, and Candida species (more likely in immunocompromised host)	**Parasitic (rare):** Echinococcus and Toxoplasma species
Autoimmune and autoinflammatory (common): Systemic autoimmune (especially systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis, scleroderma)	**Traumatic and iatrogenic (common):** Early onset: Direct injury (penetrating thoracic injury, esophageal perforation); indirect injury (nonpenetrating thoracic injury, radiation injury)

Systemic vasculitides (especially eosinophilic granulomatosis with polyangiitis or allergic granulomatosis, previously named Churg-Strauss syndrome, Horton disease, Takayasu disease, Behçet syndrome) Autoinflammatory diseases (familial Mediterranean fever, tumor necrosis factor receptor–associated periodic syndrome) Other (sarcoidosis, inflammatory bowel diseases)	Delayed onset: Pericardial injury syndromes (post–myocardial infarction syndrome, postpericardiotomy syndrome); posttraumatic, including after iatrogenic trauma (eg, coronary percutaneous intervention, pacemaker lead insertion, and radiofrequency ablation)
Drug related (rare): Lupus-like syndrome (procainamide, hydralazine, methyldopa, isoniazid, phenytoin) Hypersensitivity pericarditis with eosinophilia (eg, penicillins) Pericardial and myocardial involment (eg, antineoplastic drugs: doxorubicin, daunorubicin, cytosine arabinoside, fluorouracil, cyclophosphamide)	**Neoplastic :** Primary tumors (rare; pericardial mesothelioma) Secondary metastatic tumors (common; lung and breast cancer, lymphoma) **Metabolic (common):** Uremia, myxedema, anorexia nervosa, other rare

- **Clinical Presentation**

The classic and most usual presentation of patients with pericarditis is chest pain. The chest pain is generally sharp and pleuritic, improved by resting up and leaning ahead. Added indicators in acute pericarditis consist of (1) pericardial friction rubs, reported in about one third of situations with acute pericarditis and due to enhanced friction of inflamed pericardial layers; (2) a "regular electrocardiogram" with prevalent ST-segment altitude, reported in no greater than 60% of cases and (3) pericardial effusion (generally mild), spotted in about 60% of patients [1], [2]. Particular attributes at presentation (temperature > 38 ° C [> 100.4 ° F], subacute training course, big effusion or tamponade, and failure of nonsteroidal antiinflammatory drug [NSAID] treatment) are beneficial signs of a poor diagnosis. These qualities additionally determine patients needing hospital admission, therefore enabling triage of patients with pericarditis, considering that the presence of 1 or more of these features suggests the requirement for a hospital stay [11].

- **Prognosis**

Tamponade and constrictive pericarditis are one of the most severe complications of acute pericarditis. Tamponade could be life-threatening: the gathered fluid triggers compression of the cardiac chambers, stopping their filling. Motivate treatment is vital and consists in elimination of the pericardial effusion, typically via pericardiocentesis. In contrast, in constrictive pericarditis, compression of the cardiac tooth cavities arises from a stiffened pericardium. Constrictive pericarditis provides with right heart failure and reduced cardiac output. The conclusive treatment of this pathology is surgical removal of the pericardium, a high threat treatment. The good news is, both of these complications seldom arise adhering to acute or persisting pericarditis such as demonstrated in a testimonial of several clinical studies on pericarditis. This testimonial reports that 3 % of patients with persisting pericarditis developed to tamponade and only 1 from 296 patients created constrictive pericarditis [13].

Several researches have tried to identify patients at high danger for the growth of complications from an episode of acute pericarditis. Their goal was to establish the patients who would benefit from hospitalization for surveillance. High-risk features included: a pericardial effusion greater than 20 mm, danger elements for hemorrhagic pericardial effusion (anticoagulation, neoplasia, unexpected or iatrogenic thoracic trauma), temperature above 38 ° C, myopericarditis, pulsus paradoxus, proof of systemic inflammation, subacute development (in comparison to acute) and, finally, patients with treatment failure [14].However, it is important to note that the majority of patients present none of these attributes. Besides determining the patients with a greater danger of difficulties, these features can also help identifying those for whom an accurate etiology is more probable to be found and that would certainly profit from a much more considerable investigation.

A considerable proportion of patients with acute pericarditis additionally provide a particular degree of myocarditis, possibly due to the fact that they share numerous common etiologies, particularly viral infections. Detection of these patients relies on an elevation of cardiac biomarkers (troponins, CK-MB) and a new left ventricular dysfunction as typically shown by echocardiography [15].Besides supplying hemodynamic assistance, if required, standard advised treatment for non-ischemic left ventricular dysfunction is encouraged (β-blockers and angiotensin-converting enzyme inhibitors). In addition, since of their feasible damaging results on myocarditis, non-steroidal anti-inflammatory medications (NSAIDs) should be utilized with care in perimyocarditis. It is recommended to use a reduced dose and to favour the usage of acetylsalicylic acid. Nonetheless, some reasons for myocarditis require specific therapies, as defined in a current New England Journal of Medicine article [16].

The primary issue in the development of acute pericarditis depends on the high rate of reoccurrences, which take place, on average, in 24 % of patients, according to the biggest case-series readily available [17].This rate is about twice as frequent in recurring pericarditis.

- **Treatment options**

Various therapeutic choices are available for the therapy of patients with recurrent pericarditis. To give an evidence-based strategy to the choice of therapies, the available published literature has been evaluated, and proof to sustain a particular treatment is rated according to the level of evidence (LOE) of requirements of the ESC. The treatment of recurring pericarditis need to be targeted to the underlying aetiology as much as possible [12].If the underlying aetiology of the inflammatory pericardial illness is unidentified for the very first event of pericarditis or for the reoccurrence, and details aetiologies (such as infectious, neoplastic, autoimmune, or autoinflammatory) have not been

excluded, physicians should take into consideration examining the aetiology to select the optimum therapeutic regimens.

A lot of patients have an immune-mediated or postinfectious aetiology and the mainstay of treatment is anti-inflammatory therapy with aspirin or an NSAID plus colchicine as front runner [2], [3], [18], [19].Corticosteroids are second-line medicines in patients with contraindications or intolerance to NSAIDs, inadequate feedback to previous treatments, or details indicators (such as systemic inflammatory diseases or maternity). After two or more reappearances that have been treated with aspirin or a various NSAID (usually a trial with even more compared to one NSAID is necessitated), corticosteroids are considered integrated with colchicine. If the patient does not react sufficiently to this mix, triple therapy with an NSAID, colchicine, and steroids should be thought about to accomplish control of symptoms [23], [22].Triple-combination therapy is basically based upon expert opinion and nonrandomized observations from tertiary referral centres for the management of frequent pericarditis [24], [21], [20]. In patients that are refractory to these treatments, additional drugs (such as azathioprine, intravenous immunoglobulins, or anakinra) can be thought about on an empirical basis, provided that the evidence to sustain these treatments is basically from case collection, instance reports, and professionals agreement.

- **Corticosteroids performance and side effects**

Corticosteroid treatment was previously the first option for treating pericarditis with pericardial effusions or recurrences not replying to aspirin or NSAIDs. Nevertheless, a lot more recently, this treatment has been shown to be connected with even more adverse effects, possibly a much more prolonged disease course, and a higher recurrence danger in nonrandomized studies. In the biggest such research, [24] 100 successive patients with persistent pericarditis (either idiopathic or related to a systemic inflammatory disease or postcardiac injury disorder) were assessed according to a

procedure comparing high-dosage prednisone (1.0 mg/kg each day) vs low- to moderate-dosage prednisone (0.2-0.5 mg/kg per day). Each initial dosage was preserved for 4 weeks and then slowly tapered. After changing for confounders (age, female sex, nonidiopathic origin), only high doses of prednisone were connected with extreme unfavorable results, recurrences, and hospitalizations (hazard ratio [HR], 3.61; 95% CI, 1.96-6.63). Hospitalizations were reduced in patients treated with reduced- vs high-dosage prednisone (8.2% vs 31.4%, specifically; P =.005). Use reduced to moderate doses of corticosteroids was related to a lower reappearance rate throughout follow-up compared with high dosages (eg, prednisone, 1.0 mg/kg/d) (32.6% vs 64.7%; P =.002).

Corticosteroids could normally be efficiently used to attain rapid control of symptoms and reduction of pericardial effusion, but are connected with an extended course and additional reoccurrences, specifically if utilized at high dosages (such as prednisone 1.0 mg/kg daily or equivalent; LOE B)6,35. In a particular retrospective study on recurrent pericarditis, compared to lower doses of prednisone (0.2-- 0.5 mg/kg daily), high dosages of prednisone (1.0 mg/kg each day) were related to extreme adverse results, recurrences, and hospitalizations (HR 3.61, 95% CI 1.96-- 6.63, P patients that experience added reoccurrences throughout faster tapering (at increments of 2.5 mg). Corticosteroid usage (especially at high dosages) is connected with severe adverse effects in 25% of patients, often resulting in medication withdrawal [26].The reported negative effects consist of raised appetite, acne, mood modifications and mental health issue (depression, anxiety, insomnia), muscle mass weakness, fatty down payments in the face, stretch marks across the body (Cushing disorder), osteoporosis, diabetic issues mellitus, systemic arterial hypertension, glaucoma and cataract, increased risk of infections, and impaired development in youngsters. All these adverse impacts have been reported in patients with recurring and chronic kinds of pericarditis after prolonged therapy with corticosteroids.

These findings are shown in the European suggestions which limit using corticosteroids to refractory and repeating pericarditis or in cases of intolerance, contraindication or failure of the common therapies (NSAIDs and colchicine) [27].Patients receiving steroids for even more than 3 month ought to get osteoporosis prophylaxis: calcium, vitamin D and bisphosphonates [28].The recommended corticosteroid doses are inferred from the experience acquired in the treatment of serositis such as in lupus and various other systemic inflammatory diseases. Just like NSAIDs, corticosteroid tapering need to begin only after the resolution of symptoms and normalization of the inflammatory markers.

Conclusion:

Corticosteroid treatment was previously the initial choice for treating pericarditis with pericardial effusions or recurrences not reacting to aspirin or NSAIDs. Corticosteroids could usually be effectively utilized to accomplish quick control of symptoms and decrease of pericardial effusion. Nonetheless, more just recently, this therapy has been shown to be associated with more negative results, potentially a more prolonged illness course, especially if used at high dosages. The reported negative effects include enhanced appetite, acne, mood changes and mental health issue (depression, anxiety, insomnia), muscle weakness, fatty deposits in the face, stretch marks across the body (Cushing syndrome), osteoporosis, diabetes mellitus, systemic arterial hypertension, glaucoma and cataract, enhanced risk of infections, and damaged growth in children. All these adverse effects have been reported in patients with recurring and chronic types of pericarditis after prolonged treatment with corticosteroids.

Reference:

1. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis. Circulation. 2005;112(13):2012-2016.
2. Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522-1528.
3. Imazio M, Cecchi E, Demichelis B, et al. Myopericarditis vs viral or idiopathic acute pericarditis. Heart. 2008;94(4):498-501.
4. Kytö V, Sipilä J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation. 2014;130(18):1601- 1606.
5. Imazio M, Spodick DH, Brucato A, et al. Controversial issues in the management of pericardial diseases. Circulation. 2010;121(7):916-928.
6. LeWinter MM. Acute pericarditis. N Engl J Med. 2014;371(25):2410-2416.
7. Imazio M, Brucato A, Maestroni S, et al. Risk of constrictive pericarditis after acute pericarditis. Circulation. 2011;124(11):1270-1275.
8. Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371(12): 1121-1130.
9. Horneffer PJ, Miller RH, Pearson TA, et al. The effective treatment of postpericardiotomy syndrome after cardiac operations.J Thorac Cardiovasc Surg. 1990;100(2):292-296.
10. Imazio M, Hoit BD. Post-cardiac injury syndromes. Int J Cardiol. 2013;168(2):648-652.
11. Imazio M, Cecchi E, Demichelis B, et al. Indicators of poor prognosis of acute pericarditis. Circulation. 2007;115(21):2739-2744.
12. Gouriet F, Levy PY, Casalta JP, et al. Etiology of pericarditis in a prospective cohort of 1162 cases. Am J Med. 2015;128(7):784.e1-784.
13. Imazio M, Trinchero R, Shabetai R. Pathogenesis, management, and prevention of recurrent pericarditis. J Cardiovasc Med (Hagerstown) 2007;8:404–410.
14. Spodick DH. Risk prediction in pericarditis: who to keep in hospital? Heart. 2008;94:398–399.

15. Imazio M, Trinchero R. Myopericarditis: Etiology, management, and prognosis. Int J Cardiol. 2008;127:17–26.
16. Cooper LT Jr. Myocarditis. N Engl J Med. 2009;360:1526–1538.
17. Soler-Soler J, Sagristà-Sauleda J, Permanyer-Miralda G. Relapsing pericarditis. Heart. 2004;90:1364–1368.
18. Reuter H, Burgess LJ, Carstens ME, Doubell AF. Adenosine deaminase activity—more than a diagnostic tool in tuberculous pericarditis. Cardiovasc J S Afr. 2005;16(3):143-147.
19. Lotrionte M, Biondi-Zoccai G, Imazio M, et al. International collaborative systematic review of controlled clinical trials on pharmacologic treatments for acute pericarditis and its recurrences. Am Heart J. 2010;160(4):662-670.
20. Alabed S, Cabello JB, Irving GJ, et al. Colchicine for pericarditis. Cochrane Database Syst Rev. 2014; 8:CD010652.
21. Reuter H, Burgess L, van Vuuren W, Doubell A. Diagnosing tuberculous pericarditis. QJM. 2006;99 (12):827-839.
22. Pawlak Cieślik A, Szturmowicz M, Fijałkowska A, et al. Diagnosis of malignant pericarditis. Kardiol Pol. 2012;70(11):1147-1153.
23. Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP). Ann Intern Med. 2011;155(7):409-414.
24. Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis. Arch Intern Med. 2005;165(17):1987-1991.
25. Alraies MC, AlJaroudi W, Yarmohammadi H, et al. Usefulness of cardiac magnetic resonance-guided management in patients with recurrent pericarditis. Am J Cardiol. 2015;115(4): 542-547.
26. Vianello F, Cinetto F, Cavraro M, et al. Azathioprine in isolated recurrent pericarditis. Int J Cardiol. 2011;147(3):477-478.
27. Imazio M, Brucato A, Trinchero R, Shabetai R, Spodick D, Adler Y. Corticosteroid therapy for pericarditis: a double-edged sword. Nat Clin Pract Cardiovasc Med. 2008;5:118–119.
28. Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, Suarez-Almazor M. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev. 2000:CD001347.
29.